Aevi Genomic Medicine Overview
- Year Founded
-
2000
- Status
-
Acquired/Merged
- Employees
-
14
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$23.5M
Aevi Genomic Medicine General Information
Description
Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.
Contact Information
Website
www.aevigenomics.comCorporate Office
- 435 Devon Park Drive
- Suite 715
- Wayne, PA 19087
- United States
Corporate Office
- 435 Devon Park Drive
- Suite 715
- Wayne, PA 19087
- United States
Aevi Genomic Medicine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 03-Feb-2020 | $23.5M | Completed | Generating Revenue | ||
| 11. PIPE | 17-Oct-2017 | Completed | Generating Revenue | |||
| 10. 2PO | 24-Jun-2016 | Completed | Generating Revenue | |||
| 9. PIPE | 19-Jun-2012 | Completed | Generating Revenue | |||
| 8. Debt - General | 04-Nov-2010 | Completed | Generating Revenue | |||
| 7. PIPE | 26-May-2010 | Completed | Generating Revenue | |||
| 6. Debt - General | 23-Jun-2009 | Completed | Generating Revenue | |||
| 5. IPO | 04-Dec-2007 | Completed | Generating Revenue | |||
| 4. Angel (individual) | 19-Apr-2006 | $27K | $19.6M | Completed | Startup | |
| 3. Early Stage VC (Series B) | 25-Apr-2003 | $12.3M | $19.5M | Completed | Startup |
Aevi Genomic Medicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A1 | 4,224,339 | $0.000100 | $0.14 | $1.71 | $1.71 | 1x | $1.71 | |
| Series A | 4,224,339 | $0.000100 | $0.14 | $1.71 | $1.71 | 1x | $1.71 | 26.99% |
Aevi Genomic Medicine Comparisons
Industry
Financing
Details
Aevi Genomic Medicine Competitors (33)
One of Aevi Genomic Medicine’s 33 competitors is Palvella Therapeutics, a Formerly VC-backed company based in Wayne, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Palvella Therapeutics | Formerly VC-backed | Wayne, PA | ||||
| Limelight Bio | Formerly VC-backed | Philadelphia, PA | ||||
| TCG Lifesciences | Corporation | Kolkata, India | ||||
| Personalis | Formerly VC-backed | Fremont, CA | ||||
| OpGen | Formerly VC-backed | Rockville, MD |
Aevi Genomic Medicine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aevi Genomic Medicine Patents
Aevi Genomic Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190030128-A1 | Compositions and methods for treatment of central nervous system diseases | Inactive | 11-Jan-2016 | ||
| EP-3402531-A1 | Compositions and methods for treatment of central nervous system diseases | Inactive | 11-Jan-2016 | ||
| EP-3402531-A4 | Compositions and methods for treatment of central nervous system diseases | Inactive | 11-Jan-2016 | ||
| US-20160122713-A1 | Genetically-modified micro-organ secreting a therapeutic peptide and methods of use thereof | Inactive | 14-Oct-2014 | ||
| US-20150118187-A1 | Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof | Inactive | 24-Oct-2013 | A61K38/1816 |
Aevi Genomic Medicine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aevi Genomic Medicine Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| CIBC Capital Markets | Investment Bank | Minority | ||
| Chicago Private Investments | Other | Minority | ||
| Children's Hospital of Philadelphia | Impact Investing | Minority |
Aevi Genomic Medicine Acquisitions (1)
Aevi Genomic Medicine’s most recent deal was a Merger/Acquisition with neuroFix Therapeutics for . The deal was made on 09-Sep-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| neuroFix Therapeutics | 09-Sep-2015 | Merger/Acquisition | Drug Discovery |
Aevi Genomic Medicine ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Aevi Genomic Medicine FAQs
-
When was Aevi Genomic Medicine founded?
Aevi Genomic Medicine was founded in 2000.
-
Where is Aevi Genomic Medicine headquartered?
Aevi Genomic Medicine is headquartered in Wayne, PA.
-
What is the size of Aevi Genomic Medicine?
Aevi Genomic Medicine has 14 total employees.
-
What industry is Aevi Genomic Medicine in?
Aevi Genomic Medicine’s primary industry is Drug Discovery.
-
Is Aevi Genomic Medicine a private or public company?
Aevi Genomic Medicine is a Private company.
-
What is the current valuation of Aevi Genomic Medicine?
The current valuation of Aevi Genomic Medicine is .
-
What is Aevi Genomic Medicine’s current revenue?
The current revenue for Aevi Genomic Medicine is .
-
How much funding has Aevi Genomic Medicine raised over time?
Aevi Genomic Medicine has raised $89.5M.
-
Who are Aevi Genomic Medicine’s investors?
Alta Partners, , CIBC Capital Markets, Chicago Private Investments, and Children's Hospital of Philadelphia are 5 of 11 investors who have invested in Aevi Genomic Medicine.
-
Who are Aevi Genomic Medicine’s competitors?
Palvella Therapeutics, Limelight Bio, TCG Lifesciences, Personalis, and OpGen are some of the 33 competitors of Aevi Genomic Medicine.
-
When was Aevi Genomic Medicine acquired?
Aevi Genomic Medicine was acquired on 03-Feb-2020.
-
Who acquired Aevi Genomic Medicine?
Aevi Genomic Medicine was acquired by Avalo Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
